AbbVie’s Orilissa (elagolix) Receives Health Canada Approval to Treat Moderate-to-Severe Pain Associated with Endometriosis

 AbbVie’s Orilissa (elagolix) Receives Health Canada Approval to Treat Moderate-to-Severe Pain Associated with Endometriosis

AbbVie’s Orilissa (elagolix) Receives Health Canada Approval to Treat Moderate-to-Severe Pain Associated with Endometriosis

Shots:

  • The approval is based on two P-III studies assessing Orilissa 150 mg qd and 200 mg bid vs PBO enrolling 1,700 women with moderate to severe endometriosis pain
  • P-III studies Results: showed reduction in daily menstrual pain and non-menstrual pelvic pain @6mos.; reduction in numeric rating scale (NRS) scores @3mos.; reduction in pain during sexual intercourse @3mos.
  • Orilissa recommend doses 150mg qd and 200mg bid for up to 12mos is expected to be available in Canada from Nov’18

Click here to read full press release/ article | Ref: PRNewswire | Image: Barron

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post